
Castle Biosciences, Inc. (NASDAQ:CSTL – Free Report) – Investment analysts at KeyCorp issued their FY2026 earnings per share (EPS) estimates for Castle Biosciences in a research note issued on Thursday, November 5th. KeyCorp analyst P. Knight forecasts that the company will post earnings per share of ($0.82) for the year. KeyCorp has an “Overweight” rating and a $40.00 price target on the stock. The consensus estimate for Castle Biosciences’ current full-year earnings is ($0.82) per share. KeyCorp also issued estimates for Castle Biosciences’ Q4 2026 earnings at ($0.14) EPS and FY2027 earnings at ($0.11) EPS.
Several other research analysts have also issued reports on CSTL. BTIG Research boosted their target price on Castle Biosciences from $44.00 to $52.00 and gave the company a “buy” rating in a research report on Monday, November 9th. Wall Street Zen raised Castle Biosciences from a “hold” rating to a “buy” rating in a research note on Sunday, November 1st. Robert W. Baird increased their price target on Castle Biosciences from $39.00 to $41.00 and gave the stock an “outperform” rating in a report on Monday, November 9th. Mizuho began coverage on Castle Biosciences in a research note on Thursday, October 29th. They set an “outperform” rating and a $60.00 price target for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Castle Biosciences in a research note on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $46.50.
Castle Biosciences Stock Down 3.1%
Castle Biosciences stock opened at $32.75 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.28 and a quick ratio of 5.12. Castle Biosciences has a 1-year low of $17.72 and a 1-year high of $44.28. The company’s 50-day moving average is $34.35 and its 200 day moving average is $28.30.
Castle Biosciences (NASDAQ:CSTL – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.22. Castle Biosciences had a negative net margin of 6.10% and a negative return on equity of 4.89%. The company had revenue of $101.95 million during the quarter, compared to analyst estimates of $92.76 million.
Hedge Funds Weigh In On Castle Biosciences
Several institutional investors and hedge funds have recently added to or reduced their stakes in CSTL. BlackRock Inc. purchased a new position in Castle Biosciences during the 2nd quarter worth $78,513,000. Jefferies Financial Group Inc. acquired a new position in Castle Biosciences during the 2nd quarter valued at about $15,440,000. AIGH Capital Management LLC purchased a new stake in Castle Biosciences in the second quarter valued at about $13,001,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Castle Biosciences in the second quarter valued at about $7,912,000. Finally, Advisors Capital Management LLC purchased a new stake in Castle Biosciences in the second quarter valued at about $5,681,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.
Insider Activity
In other news, insider Derek Maetzold sold 12,428 shares of the business’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $33.20, for a total value of $412,609.60. Following the completion of the transaction, the insider directly owned 21,479 shares of the company’s stock, valued at approximately $713,102.80. The trade was a 36.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Kristen M. Oelschlager sold 12,384 shares of the business’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $34.42, for a total value of $426,257.28. Following the completion of the transaction, the chief operating officer directly owned 72,649 shares of the company’s stock, valued at approximately $2,500,578.58. The trade was a 14.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 132,300 shares of company stock worth $4,531,018. Company insiders own 6.10% of the company’s stock.
About Castle Biosciences
Castle Biosciences, Inc. is a molecular diagnostics company that develops and commercializes tests intended to help physicians make personalized treatment and care decisions. Its tests analyze biological features of tissue to provide information about disease behavior and patient risk. The company’s portfolio includes DecisionDx tests for conditions such as cutaneous melanoma, cutaneous squamous cell carcinoma and uveal melanoma. It also offers TissueCypher, a test designed to assess progression risk in patients with Barrett’s esophagus.
Recommended Stories
- Five stocks we like better than Castle Biosciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
